EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT

Bone Marrow Transplantation

Volumn 42, Issue 3, 2008, Pages 181-186

  Ocheni, S ^a,b   Kroeger, N ^a   Zabelina, T ^a   Sobottka, I ^a   Ayuk, F ^a   Wolschke, C ^a   Muth, A ^a   Lellek, H ^a   Petersen, L ^a   Erttmann, R ^a   Kabisch, H ^a   Zander, A R ^a   Bacher, U ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b University of Nigeria Enugu Campus ^*  (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; FOSCARNET SODIUM; GANCICLOVIR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONCURRENT INFECTION; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SURVEILLANCE; DONOR LYMPHOCYTE INFUSION; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; MYCOSIS; PARASITOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STANDARDIZATION; VIRUS INFECTION; VIRUS REACTIVATION;

ACYCLOVIR; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; GRAFT VS HOST DISEASE; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSION; MIDDLE AGED; MYCOSES; PARASITIC DISEASES; STEM CELL TRANSPLANTATION; TISSUE DONORS; VIRUS ACTIVATION;

EID: 50049101434     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.150     Document Type: Article

References (27)

1. Markasz L, Stuber G, Flaberg E, Jernberg AG, Eksborg S, Olah E et al. Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells. BMC Cancer 2006; 6: 265.
2. Bower M. The management of lymphoma in the immunosuppressed patient. Best Pract Res Clin Haematol 2002; 15: 517-532.
3. Aalto SM, Juvonen E, Tarkkanen J, Volin L, Ruutu T, Mattila PS. et al. Lymphoproliferative disease after allogeneic stem cell transplantation - pre-emptive diagnosis by quantification of Epstein-Barr virus DNA in serum. J Clin Virol 2003; 28: 275-283.
4. Juvonen E, Aalto SM, Tarkkanen J, Volin L, Mattila PS, Knuutila S et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosupressive treatment. Bone Marrow Transplant 2003; 32: 97-102.
5. Martin-Gomez MA, Pena M, Cabello M, Burgos D, Gutierrez C, Sola E et al. Posttransplant lymphoproliferative disease: A series of 23 cases. Transplant Proc 2006; 38: 2448-2450.
6. Craig FE, Johnson LR, Harvey SA, Nalesnik MA, Luo JH, Bhattacharya SD et al. Gene expression profiling of Epstein-Barr virus-positive and -negative monomorphic B-cell post-transplant lymphoproliferative disorders. Diagn Mol Pathol 2007; 16: 158-168.
7. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: A review. Bone Marrow Transplant 2003; 31: 145-155.
8. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow- SH. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: A distinct entity? Am J Surg Pathol 2000; 24: 375-385.
9. Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Kim HJ et al. Clinical characteristics and outcomes of posttransplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation in Korea. J Korean Med Sci 2006; 21: 259-264.
10. Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807-814.
11. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-1555.
12. Gartner BC, Schafer H, Marggraff K, Eisele G, Schafer M, Dilloo D et al. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol 2002; 40: 351-358.
13. van Esser JW, Niesters HG, van der HB, Meijer E, Osterhaus AD, Gratama JW et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364-4369.
14. van Esser JW, van der HB, Meijer E, Niestets FIG, Trenschel R, Thijsen SF et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972-978.
15. Annels NE, Kalpoe JS, Bredius RG, Claas EC, Kroes AC, Hislop AD et al. Management of Epstein-Barr virus (EBV) reactivation after allogencic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis 2006; 42: 1743-1748.
16. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
17. Przepiorka D, Weisdorf D, Martin P, Klingernann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
18. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988: 6: 1562-1568.
19. Boyle GJ, Michaels MG, Webber SA, Knisely AS, Kurland G, Cipriani LA et al. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr 1997; 131: 309-313.
20. Webber SA, Naftel DC, Fricker FJ, Olesnevich P, Blume ED, Addonizio L et al. Lymphoproliferative disorders after paediatric heart transplantation: A multi-institutional study. Lancet 2006; 367 233-239.
21. Lankester AC, van Tol MJ, Vossen JM, Kroes AC, Claas E. Epstein-Barr virus (EBV)-DNA quantification in pediatric allogenic stem cell recipients: Prediction of EBV-associated lymphoproliferative disease. Blood 2002; 99: 2630-2631.
22. Clave E, Agbalika F, Bajzik V, Peffault de LR, Trillard M, Rabian C et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: Relationship between viral load, EBV-specific T-cell reconstitution and rituximab theraphy. Transplantation 2004; 77 76-84.
23. Meij P, van Esser JW, Niesters HG, van BD, Miedema F, Blake N et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progreszive FBV reactivation and lymphoproliferative disease. Blood 2003; 101: 4290-4297.
24. Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis 2007; 39: 235 244.
25. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517-1525.
26. Haque T, Amlot PL, Helling N, Thomas JA, Sweny P, Rolles K et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol 1998; 160: 6204-6209.
27. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lympho proliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-1191.